trending Market Intelligence /marketintelligence/en/news-insights/trending/TB8xM04t1uja8kEzh68bRg2 content esgSubNav
In This List

Mylan to recall ulcer drug from US market over cancer-causing impurity

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Mylan to recall ulcer drug from US market over cancer-causing impurity

Mylan NV initiated a voluntary recall of three lots of its Nizatidine capsules in the U.S. market after detecting traces of a potentially cancer-causing substance called N-Nitrosodimethylamine, commonly known as NDMA.

The U.K.-based pharmaceutical company did not receive any reports of adverse events directly related to the recalled batches.

Nizatidine is used to treat ulcers of the stomach and intestines and prevent them from coming back after they have healed. It is also used to treat certain other stomach and throat problems including gastroesophageal reflux disease. The medication works by decreasing the amount of acid the stomach makes.

Previously, Mylan was among the companies that recalled several lots of their generic ranitidine drugs from the U.S. market after finding elevated levels of NDMA in the products.